Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 30, 2017 08:00 ET | Source: MyoKardia, Inc.

MyoKardia to Present at Two Upcoming Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
August 14, 2017 11:14 ET | Source: MyoKardia, Inc.

MyoKardia Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia”), a clinical stage biopharmaceutical company pioneering a precision medicine approach for...
August 10, 2017 08:00 ET | Source: MyoKardia, Inc.

MyoKardia to Present at 2017 Wedbush PacGrow Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
August 08, 2017 20:16 ET | Source: MyoKardia, Inc.

MyoKardia Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia”), a clinical stage biopharmaceutical company pioneering a precision medicine approach for...
August 07, 2017 16:01 ET | Source: MyoKardia, Inc.

MyoKardia Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia” or the “Company”), a clinical stage biopharmaceutical company pioneering a precision...
August 07, 2017 07:19 ET | Source: MyoKardia, Inc.

MyoKardia Reports Second Quarter 2017 Financial Results and Operational Progress

Positive Topline Results in First Patient Cohort of Phase 2 PIONEER-HCM Study Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT (5:30 a.m. PDT) SOUTH SAN FRANCISCO, Calif., Aug. ...
August 07, 2017 07:00 ET | Source: MyoKardia, Inc.

MyoKardia Reports Positive Topline Results in Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) in Symptomatic, Obstructive Hypertrophic Cardiomyopathy

Phase 2 Study Met Primary and Key Secondary Endpoints Results from First Patient Cohort of PIONEER-HCM Accepted for Oral Presentation at Heart Failure Society of America’s 21st Annual Scientific...
July 31, 2017 08:01 ET | Source: MyoKardia, Inc.

MyoKardia to Announce Second Quarter 2017 Financial Results and Host Conference Call on Monday, August 7, 2017

SOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
May 09, 2017 16:02 ET | Source: MyoKardia, Inc.

MyoKardia Reports First Quarter 2017 Financial Results and Operational Progress

Company to Host Conference Call and Webcast Today at 2:00 PM PT (5:00 PM ET) SOUTH SAN FRANCISCO, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage...
May 02, 2017 08:30 ET | Source: MyoKardia, Inc.

MyoKardia to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 9, 2017

SOUTH SAN FRANCISCO, Calif., May 02, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...